scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0140-6736(20)31790-6 |
P698 | PubMed publication ID | 32877651 |
P50 | author | Petr Widimský | Q12045089 |
Michał Tendera | Q48860774 | ||
P2093 | author name string | Roberto Ferrari | |
Ian Ford | |||
Nicolas Danchin | |||
Kim Fox | |||
Anne Correges | |||
ATPCI investigators | |||
Jean Pascal Challeton | |||
P2860 | cites work | Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials | Q28272636 |
The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase | Q28373346 | ||
Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry | Q30841815 | ||
Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study | Q34290387 | ||
Optimal medical therapy with or without PCI for stable coronary disease | Q34612445 | ||
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial | Q35810820 | ||
Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis | Q36370257 | ||
Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand | Q43811969 | ||
Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis | Q45829479 | ||
Expert consensus document: A 'diamond' approach to personalized treatment of angina | Q48022963 | ||
2018 ESC/EACTS Guidelines on myocardial revascularization | Q57071561 | ||
Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention | Q89711644 | ||
Initial Invasive or Conservative Strategy for Stable Coronary Disease | Q90754553 | ||
Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization | Q90877897 | ||
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline charact | Q91644078 | ||
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial | Q91856170 | ||
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes | Q95729536 | ||
Survival of Patients With Angina Pectoris Undergoing Percutaneous Coronary Intervention With Intracoronary Pressure Wire Guidance | Q96131639 | ||
P921 | main subject | placebo-controlled trial | Q108853737 |
P577 | publication date | 2020-08-28 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial |
Q99365826 | Trimetazidine not beneficial after PCI | cites work | P2860 |
Search more.